Advertisement

Herz

, Volume 44, Issue 5, pp 398–404 | Cite as

Efficacy of aliskiren supplementation for heart failure

A meta-analysis of randomized controlled trials
  • Y. Luo
  • Q. ChenEmail author
Review articles

Abstract

Background

Aliskiren might be beneficial for heart failure. However, the results of various studies are controversial. We conducted a systematic review and meta-analysis to explore the efficacy of aliskiren supplementation for heart failure.

Methods

PubMed, Embase, Web of Science, EBSCO, and the Cochrane Library databases were systematically searched. Randomized controlled trials (RCTs) assessing the efficacy of aliskiren for heart failure were included. Two investigators independently searched for articles, extracted data, and assessed the quality of included studies. The meta-analysis was performed using the random-effect model.

Results

Five RCTs comprising 1973 patients were included in the meta-analysis. Compared with control interventions in heart failure, aliskiren supplementation was found to significantly reduce NT-proBNP levels (standardized mean difference [SMD] = −0.12; 95% CI = −0.21 to −0.03 pg/ml; p = 0.008) and plasma renin activity (SMD = −0.66; 95% CI = −0.89 to −0.44 ng/ml.h; p < 0.00001) while increasing plasma renin concentration (SMD = 0.52; 95% CI = 0.30–0.75 ng/l; p < 0.00001); however, it demonstrated no significant influence on BNP levels (SMD = −0.08; 95% CI = −0.31–0.15 pg/ml; p = 0.49), mortality (RR = 0.97; 95% CI = 0.79–1.20; p = 0.79), aldosterone levels (SMD = −0.09; 95% CI = −0.32–0.14 pmol/l; p = 0.44), adverse events (RR = 3.03; 95% CI = 0.18–49.51; p = 0.44), and serious adverse events (RR = 1.34; 95% CI = 0.54–3.33; p = 0.53).

Conclusion

Aliskiren supplementation was found to significantly decrease NT-proBNP levels and plasma renin activity and to improve plasma renin concentration in the setting of heart failure.

Keywords

Heart failure Renin Renin–angiotensin–aldosterone system Brain natriuretic peptide Meta-analysis 

Wirksamkeit der Aliskiren-Supplementierung bei Herzinsuffizienz

Eine Metaanalyse randomisierter kontrollierter Studien

Zusammenfassung

Hintergrund

Aliskiren könnte vorteilhaft bei Herzinsuffizienz wirken. Jedoch führten verschiedene Studien zu kontroversen Ergebnissen. Die Autoren erstellten eine systematische Übersicht und Metaanalyse, um die Wirksamkeit der Supplementierung von Aliskiren bei Herzinsuffizienz zu ermitteln.

Methoden

Die Datenbanken PubMed, Embase, Web of Science, EBSCO und die Cochrane Library wurden systematisch durchsucht. In die Auswertung aufgenommen wurden randomisierte kontrollierte Studien, in denen die Wirksamkeit von Aliskiren bei Herzinsuffizienz untersucht wurde. Zwei Untersucher ermittelten unabhängig voneinander entsprechende Beiträge, extrahierten Daten und bewerteten die Qualität der in die Auswertung aufgenommenen Studien. Für die Durchführung der Metaanalyse wurde das Random-Effects-Modell eingesetzt.

Ergebnisse

Es wurden 5 Studien mit 1973 Patienten in die Metaanalyse eingeschlossen. Im Vergleich zu Kontrollinterventionen bei Herzinsuffizienz zeigte sich, dass die Supplementierung von Aliskiren zu einer signifikanten Senkung der Werte für NT-proBNP (n-terminales „pro brain natriuretic peptide“; standardisierte Mittelwertdifferenz, SMD: −0,12; 95%-Konfidenzintervall, 95%-KI: −0,21 bis −0,03 pg/ml; p = 0,008) und Plasmareninaktivität (SMD: −0,66; 95% -KI: −0,89 bis −0,44 ng/ml.h; p < 0,00001) führte, während es zum Anstieg der Plasmareninkonzentration kam (SMD: 0,52; 95% -KI: 0,30–0,75 ng/l; p < 0,00001); jedoch zeigte sich kein signifikanter Einfluss auf den BNP-Wert (SMD: −0,08; 95% -KI: −0,31–0,15 pg/ml; p = 0,49), die Mortalität (relatives Risiko, RR: 0,97; 95% -KI: 0,79–1,20; p = 0,79), Aldosteronwerte (SMD: −0,09; 95% -KI: −0,32–0,14 pmol/l; p = 0,44), unerwünschte Ereignisse (RR: 3,03; 95% -KI: 0,18–49,51; p = 0,44) und schwere unerwünschte Ereignisse (RR: 1,34; 95% -KI: 0,54–3,33; p = 0,53).

Schlussfolgerung

Es stellte sich heraus, dass die Supplementierung von Aliskiren im Rahmen einer Herzinsuffizienz zu einer signifikanten Senkung der Werte für NT-proBNP und für die Plasmareninaktivität führte sowie zur Verbesserung der Plasmareninkonzentration.

Schlüsselwörter

Herzinsuffizienz Renin Renin-Angiotensin-Aldosteron-System „Brain natriuretic peptide“ Metaanalyse 

Notes

Compliance with ethical guidelines

Conflict of interest

Y. Luo and Q. Chen declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Braam B, Cupples WA, Joles JA, Gaillard C (2012) Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 17:161–175CrossRefGoogle Scholar
  2. 2.
    Palmer BF (2002) Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347:1256–1261CrossRefGoogle Scholar
  3. 3.
    Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E et al (2016) Defibrillator implantation in patients with Nonischemic systolic heart failure. N Engl J Med 375:1221–1230CrossRefGoogle Scholar
  4. 4.
    Sulzberger L, Baillie R, Itinteang T, de Jong S, Marsh R, Leadbitter P et al (2016) Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma. J Plast Reconstr Aesthet Surg 69:381–386CrossRefGoogle Scholar
  5. 5.
    Goessler K, Polito M, Cornelissen VA (2016) Effect of exercise training on the renin-angiotensin-aldosterone system in healthy individuals: a systematic review and meta-analysis. Hypertens Res 39:119–126CrossRefGoogle Scholar
  6. 6.
    Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469CrossRefGoogle Scholar
  7. 7.
    Smilde TD, Hillege HL, Navis G, Boomsma F, de Zeeuw D, van Veldhuisen DJ (2004) Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J 148:165–172CrossRefGoogle Scholar
  8. 8.
    Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A et al (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210CrossRefGoogle Scholar
  9. 9.
    Braam B, Koomans HA (1996) Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 5:89–96CrossRefGoogle Scholar
  10. 10.
    Nijst P, Verbrugge FH, Martens P, Bertrand PB, Dupont M, Francis GS et al (2017) Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. J Renin Angiotensin Aldosterone Syst 18:1470320317729919CrossRefGoogle Scholar
  11. 11.
    Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273:1450–1456CrossRefGoogle Scholar
  12. 12.
    Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR (2004) Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141:693–704CrossRefGoogle Scholar
  13. 13.
    Ahad A, Al-Mohizea AM, Al-Jenoobi FI, Aqil M (2016) Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. Drug Deliv 23:579–590CrossRefGoogle Scholar
  14. 14.
    Szymanski MK, Damman K, van Veldhuisen DJ, van Gilst WH, Hillege HL, de Boer RA (2011) Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. Am Heart J 162:487–493CrossRefGoogle Scholar
  15. 15.
    de Boer RA, Schroten NF, Bakker SJ, Mahmud H, Szymanski MK, van der Harst P et al (2012) Plasma renin and outcome in the community: data from PREVEND. Eur Heart J 33:2351–2359CrossRefGoogle Scholar
  16. 16.
    Hsu FY, Lin FJ, Ou HT, Huang SH, Wang CC (2017) Renoprotective effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kidney Blood Press Res 42:358–368CrossRefGoogle Scholar
  17. 17.
    Seed A, Gardner R, McMurray J, Hillier C, Murdoch D, MacFadyen R et al (2007) Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 9:1120–1127CrossRefGoogle Scholar
  18. 18.
    McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL et al (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17–24CrossRefGoogle Scholar
  19. 19.
    Schroten NF, Damman K, Hemmelder MH, Voors AA, Navis G, Gaillard CA et al (2015) Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Am Heart J 169:693–701e3CrossRefGoogle Scholar
  20. 20.
    Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:1125–1135CrossRefGoogle Scholar
  21. 21.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefGoogle Scholar
  22. 22.
    Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 (www.cochrane-handbook.org)Google Scholar
  23. 23.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefGoogle Scholar
  24. 24.
    Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982–989CrossRefGoogle Scholar
  25. 25.
    Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M et al (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 13:755–764CrossRefGoogle Scholar
  26. 26.
    Fisher ND, Danser JAH, Nussberger J, Dole WP, Hollenberg NK (2008) Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117:3199–3205CrossRefGoogle Scholar
  27. 27.
    Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AH (2011) Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens 29:2454–2461CrossRefGoogle Scholar
  28. 28.
    Kovarik JJ, Kopecky C, Antlanger M, Domenig O, Kaltenecker CC, Werzowa J et al (2017) Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. J Heart Lung Transplant 36:355–365CrossRefGoogle Scholar
  29. 29.
    Qi YF, Zhang J, Wang L, Shenoy V, Krause E, Oh SP et al (2016) Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. J Mol Med 94:37–49CrossRefGoogle Scholar
  30. 30.
    Ljungman S, Laragh JH, Cody RJ (1990) Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39(Suppl 4):10–21 (discussion 2–4)CrossRefGoogle Scholar
  31. 31.
    Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L et al (2006) Incremental prognostic value of changes in B‑type natriuretic peptide in heart failure. Am J Med 119:70e23–70e30CrossRefGoogle Scholar
  32. 32.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiology MedicalJiangjin Central Hospital of ChongqingChongqingChina

Personalised recommendations